Literature DB >> 21134451

Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions.

Susan L Baldwin1, Christopher B Fox, Mark A Pallansch, Rhea N Coler, Steven G Reed, Martin Friede.   

Abstract

The use of inactivated poliovirus vaccines (IPV) will be required to achieve, world-wide eradication of polio. The current expense of IPV is however prohibitive for, some countries, and therefore efforts to decrease the costs of the vaccine are a high, priority. Our results show that the addition of oil-in-water emulsion adjuvants to an, inactivated trivalent poliovirus vaccine are dose-sparing and are capable of enhancing, neutralizing antibody titers in the rat potency model.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21134451     DOI: 10.1016/j.vaccine.2010.11.043

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

Review 1.  Key roles of adjuvants in modern vaccines.

Authors:  Steven G Reed; Mark T Orr; Christopher B Fox
Journal:  Nat Med       Date:  2013-12-05       Impact factor: 53.440

2.  History of polio vaccination.

Authors:  Anda Baicus
Journal:  World J Virol       Date:  2012-08-12

3.  Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains.

Authors:  Janny Westdijk; Patrick Koedam; Mario Barro; Benjamin P Steil; Nicolas Collin; Thomas S Vedvick; Wilfried A M Bakker; Peter van der Ley; Gideon Kersten
Journal:  Vaccine       Date:  2013-01-09       Impact factor: 3.641

Review 4.  Adjuvants and inactivated polio vaccine: a systematic review.

Authors:  Jennifer Hawken; Stephanie B Troy
Journal:  Vaccine       Date:  2012-10-03       Impact factor: 3.641

5.  Development and in vitro evaluation of a nanoemulsion for transcutaneous delivery.

Authors:  Grace Ledet; Sarala Pamujula; Valencia Walker; Shana Simon; Richard Graves; Tarun K Mandal
Journal:  Drug Dev Ind Pharm       Date:  2013-04-19       Impact factor: 3.225

6.  Advax-CpG Adjuvant Provides Antigen Dose-Sparing and Enhanced Immunogenicity for Inactivated Poliomyelitis Virus Vaccines.

Authors:  Yoshikazu Honda-Okubo; Jeremy Baldwin; Nikolai Petrovsky
Journal:  Pathogens       Date:  2021-04-21

Review 7.  The final stages of the global eradication of poliomyelitis.

Authors:  Nicholas C Grassly
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-06-24       Impact factor: 6.237

8.  Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01.

Authors:  Jes Dietrich; Lars Vibe Andreasen; Peter Andersen; Else Marie Agger
Journal:  PLoS One       Date:  2014-06-23       Impact factor: 3.240

9.  From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.

Authors:  Rhea N Coler; Malcolm S Duthie; Kimberly A Hofmeyer; Jeffery Guderian; Lakshmi Jayashankar; Julie Vergara; Tom Rolf; Ayesha Misquith; John D Laurance; Vanitha S Raman; H Remy Bailor; Natasha Dubois Cauwelaert; Steven J Reed; Aarthy Vallur; Michelle Favila; Mark T Orr; Jill Ashman; Prakash Ghosh; Dinesh Mondal; Steven G Reed
Journal:  Clin Transl Immunology       Date:  2015-04-10

10.  Thermostabilization of inactivated polio vaccine in PLGA-based microspheres for pulsatile release.

Authors:  Stephany Y Tzeng; Rohiverth Guarecuco; Kevin J McHugh; Sviatlana Rose; Evan M Rosenberg; Yingying Zeng; Robert Langer; Ana Jaklenec
Journal:  J Control Release       Date:  2016-05-11       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.